In the case of colorectal carcinoma and other malignancies associated with MSI, the role of anti-PD-1 and PD-L1 for treatment purposes is well-known and accepted by the United States Food and Drug Administration. This evidence concerns the gene PDCD1 and colorectal carcinoma.